You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

PEGCETACOPLAN - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for pegcetacoplan and what is the scope of patent protection?

Pegcetacoplan is the generic ingredient in two branded drugs marketed by Apellis Pharms and is included in two NDAs. There are thirteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Pegcetacoplan has one hundred and ninety-three patent family members in twenty-six countries.

One supplier is listed for this compound.

Summary for PEGCETACOPLAN
International Patents:193
US Patents:13
Tradenames:2
Applicants:1
NDAs:2
Finished Product Suppliers / Packagers: 1
Clinical Trials: 19
What excipients (inactive ingredients) are in PEGCETACOPLAN?PEGCETACOPLAN excipients list
DailyMed Link:PEGCETACOPLAN at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for PEGCETACOPLAN
Generic Entry Dates for PEGCETACOPLAN*:
Constraining patent/regulatory exclusivity:
Dosage:
SOLUTION;SUBCUTANEOUS
Generic Entry Dates for PEGCETACOPLAN*:
Constraining patent/regulatory exclusivity:
Dosage:
SOLUTION;INTRAVITREAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for PEGCETACOPLAN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Roswell Park Cancer InstitutePhase 2
National Cancer Institute (NCI)Phase 2
Swedish Orphan BiovitrumPhase 3

See all PEGCETACOPLAN clinical trials

Pharmacology for PEGCETACOPLAN
Drug ClassComplement Inhibitor
Mechanism of ActionComplement Inhibitors

US Patents and Regulatory Information for PEGCETACOPLAN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Apellis Pharms SYFOVRE pegcetacoplan SOLUTION;INTRAVITREAL 217171-001 Feb 17, 2023 RX Yes Yes 7,888,323 ⤷  Subscribe Y ⤷  Subscribe
Apellis Pharms EMPAVELI pegcetacoplan SOLUTION;SUBCUTANEOUS 215014-001 May 14, 2021 RX Yes Yes ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Apellis Pharms SYFOVRE pegcetacoplan SOLUTION;INTRAVITREAL 217171-001 Feb 17, 2023 RX Yes Yes 10,125,171 ⤷  Subscribe Y ⤷  Subscribe
Apellis Pharms EMPAVELI pegcetacoplan SOLUTION;SUBCUTANEOUS 215014-001 May 14, 2021 RX Yes Yes ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Apellis Pharms EMPAVELI pegcetacoplan SOLUTION;SUBCUTANEOUS 215014-001 May 14, 2021 RX Yes Yes 10,035,822 ⤷  Subscribe Y ⤷  Subscribe
Apellis Pharms SYFOVRE pegcetacoplan SOLUTION;INTRAVITREAL 217171-001 Feb 17, 2023 RX Yes Yes 10,875,893 ⤷  Subscribe Y ⤷  Subscribe
Apellis Pharms SYFOVRE pegcetacoplan SOLUTION;INTRAVITREAL 217171-001 Feb 17, 2023 RX Yes Yes 9,169,307 ⤷  Subscribe Y ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for PEGCETACOPLAN

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Swedish Orphan Biovitrum AB (publ) Aspaveli pegcetacoplan EMEA/H/C/005553
Aspaveli is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who are anaemic after treatment with a C5 inhibitor for at least 3 months.
Authorised no no yes 2021-12-13
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for PEGCETACOPLAN

Country Patent Number Title Estimated Expiration
European Patent Office 2707384 ANALOGUES DE LA COMPSTATINE CIBLÉS, À LONGUE DURÉE D'ACTION, RÉACTIFS AUX CELLULES, ET LEURS UTILISATIONS (CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND USES THEREOF) ⤷  Subscribe
Australia 2006302212 Compstatin and analogs thereof for eye disorders ⤷  Subscribe
World Intellectual Property Organization (WIPO) 2007084765 ⤷  Subscribe
Russian Federation 2013149956 КЛЕТОЧНО-РЕАКТИВНЫЕ АНАЛОГИ КОМПСТАТИНА, АНАЛОГИ КОМПСТАТИНА ДЛИТЕЛЬНОГО ДЕЙСТВИЯ ИЛИ АНАЛОГИ КОМПСТАТИНА НАЦЕЛЕННОГО ДЕЙСТВИЯ И ИХ ПРИМЕНЕНИЕ ⤷  Subscribe
Japan 2013531030 ⤷  Subscribe
Canada 3059304 SCHEMAS POSOLOGIQUES ET COMPOSITIONS ET PROCEDES ASSOCIES (DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS) ⤷  Subscribe
Denmark 2920201 ⤷  Subscribe
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for PEGCETACOPLAN

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
3660033 122022000034 Germany ⤷  Subscribe PRODUCT NAME: PEGCETACOPLAN; REGISTRATION NO/DATE: EU/1/21/1595 20211213
3660033 PA2022010 Lithuania ⤷  Subscribe PRODUCT NAME: PEGCETACOPLANAS ; REGISTRATION NO/DATE: EU/1/21/1595 20211213
3660033 2022C/522 Belgium ⤷  Subscribe PRODUCT NAME: PEGCETACOPLAN; AUTHORISATION NUMBER AND DATE: EU/1/21/1595 20211214
3660033 CR 2022 00023 Denmark ⤷  Subscribe PRODUCT NAME: PEGCETACOPLAN; REG. NO/DATE: EU/1/21/1595 20211214
3660033 2022017 Norway ⤷  Subscribe PRODUCT NAME: PEGCETACOPLAN; REG. NO/DATE: EU/1/21/1595 20211216
3660033 301178 Netherlands ⤷  Subscribe PRODUCT NAME: PEGCETACOPLAN; REGISTRATION NO/DATE: EU/1/21/1595 20211214
3660033 LUC00265 Luxembourg ⤷  Subscribe PRODUCT NAME: PEGCETACOPLAN; AUTHORISATION NUMBER AND DATE: EU/1/21/1595 20211214
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

PEGCETACOPLAN Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Pegcetacoplan

Introduction to Pegcetacoplan

Pegcetacoplan, marketed by Apellis Pharmaceuticals as Empaveli for certain blood disorders and as Syfovre for eye conditions, is a synthetic cyclic peptide conjugated to a polyethylene glycol polymer. It functions as a targeted C3 inhibitor, regulating excessive complement activation that leads to various serious diseases[4].

Clinical Indications and Approvals

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Pegcetacoplan is approved to treat adult patients with PNH, a rare blood disorder. It has shown significant efficacy in reducing the symptoms associated with this condition[4].

Geographic Atrophy

In early 2023, the FDA approved pegcetacoplan (Syfovre) for the treatment of geographic atrophy, an eye condition. Despite initial strong sales in the U.S., the drug faced setbacks due to concerns over a rare but serious side effect and a recommendation for rejection by European regulators, although Apellis has requested a re-examination[1].

Kidney Diseases

Recent trials have demonstrated the drug's potential in treating kidney diseases such as C3 glomerulopathy (C3G) and primary immunoglobulin A (IgA) nephropathy. The positive 6-month Phase 3 VALIANT results have prompted Apellis to plan an FDA filing for these indications in early 2025[2].

Market Competition

Comparison with Iptacopan

Pegcetacoplan faces competition from iptacopan (Fabhalta), another drug approved for PNH and IgA nephropathy. Analysts suggest that the strong data from pegcetacoplan's trials may force investors to reconsider their expectations regarding market share between these two drugs[1].

Emerging Therapies

The market for PNH and other related diseases is expected to see the launch of late-stage emerging therapies, which could significantly impact the dominance of pegcetacoplan. Companies are developing novel approaches to treat these conditions, posing potential competition[4].

Financial Performance

Revenue Growth

In the third quarter of 2024, Apellis generated $196.8 million in revenues, with $176.6 million coming from U.S. net product sales. Syfovre (pegcetacoplan injection) contributed $152.0 million, showing a 7% quarter-over-quarter growth in demand[2].

Cost of Sales and Operating Expenses

The cost of sales increased to $33.6 million in the third quarter of 2024, compared to $22.4 million in the same period of 2023. Operating expenses, including research and development and selling, general, and administrative costs, totaled $244.1 million for the quarter[2].

Cash and Cash Equivalents

As of September 30, 2024, Apellis had $396.9 million in cash and cash equivalents. The company projects that its current revenues and cash reserves will be sufficient to fund operations until it reaches positive cash flow[2].

Regulatory Milestones

FDA Feedback and Future Filings

Following positive feedback from the FDA, Apellis is on track to file a supplemental New Drug Application (sNDA) seeking approval for pegcetacoplan in C3G and primary IC-MPGN in early 2025[2].

European Regulatory Status

Despite the European Medicines Agency's (EMA) recommendation to reject Syfovre, Apellis has initiated a re-examination process. A final decision is expected in the fourth quarter of 2024[3].

Clinical Trials and Data

Phase 3 VALIANT Results

The 6-month Phase 3 VALIANT results showed significant efficacy of pegcetacoplan in reducing urine protein levels by 68% compared to placebo. This data is crucial for the upcoming FDA filing[1].

Phase 2 NOBLE Study

Positive top-line data from the Phase 2 NOBLE study, investigating pegcetacoplan in post-transplant recurrence of primary IC-MPGN and C3G, further supports the drug's potential in kidney diseases[5].

Analyst Insights

Market Share Reconsideration

Analysts like Steven Seedhouse from Raymond James suggest that the strong data from pegcetacoplan's trials may force investors to reconsider their expectations regarding its market share versus iptacopan[1].

Financial Projections

Given the positive clinical data and growing demand for Syfovre, analysts are optimistic about Apellis's financial trajectory. The company's ability to manage costs and drive revenue growth is seen as a key factor in its future success[2].

Market Forecasts

Sales Projections

The market for pegcetacoplan is expected to expand significantly from 2023 to 2032, driven by increasing healthcare spending and the drug's efficacy in treating various conditions. Forecasted sales data indicate a growing market size that will allow drug manufacturers to penetrate deeper into the market[4].

Competitive Landscape

The launch of late-stage emerging therapies will significantly impact the market dynamics. Companies are focusing on novel approaches to treat diseases, which could challenge pegcetacoplan's dominance but also present opportunities for growth and innovation[4].

Conclusion

Pegcetacoplan, with its diverse clinical indications and strong clinical trial data, is poised for significant market impact. Despite facing competition and regulatory challenges, the drug's financial trajectory looks promising, driven by growing demand and expanding market opportunities.

Key Takeaways

  • Clinical Efficacy: Pegcetacoplan has shown strong efficacy in treating PNH, geographic atrophy, and potential in kidney diseases.
  • Market Competition: The drug faces competition from iptacopan and emerging therapies.
  • Financial Performance: Apellis has seen revenue growth and manages its costs effectively.
  • Regulatory Milestones: Upcoming FDA filings and re-examination in Europe are critical.
  • Market Forecasts: The market is expected to expand significantly from 2023 to 2032.

FAQs

Q: What is pegcetacoplan used for?

Pegcetacoplan is used to treat paroxysmal nocturnal hemoglobinuria (PNH), geographic atrophy, and is being investigated for use in kidney diseases such as C3 glomerulopathy (C3G) and primary immunoglobulin A (IgA) nephropathy.

Q: What are the key competitors for pegcetacoplan?

The key competitor for pegcetacoplan is iptacopan (Fabhalta), which is also approved for PNH and IgA nephropathy.

Q: How has the financial performance of Apellis been with pegcetacoplan?

Apellis has generated significant revenues from pegcetacoplan, with $196.8 million in revenues in the third quarter of 2024, and the company projects sufficient cash reserves to fund operations until reaching positive cash flow.

Q: What are the regulatory challenges facing pegcetacoplan in Europe?

Pegcetacoplan (Syfovre) faced a recommendation for rejection by European regulators, but Apellis has initiated a re-examination process with a final decision expected in the fourth quarter of 2024.

Q: What are the market forecasts for pegcetacoplan?

The market for pegcetacoplan is expected to expand significantly from 2023 to 2032, driven by increasing healthcare spending and the drug's efficacy in treating various conditions.

Sources

  1. Yahoo Finance: Apellis plans FDA filing after drug success in kidney trial.
  2. Apellis Pharmaceuticals: Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results.
  3. Apellis Pharmaceuticals: Apellis Pharmaceuticals Reports Second Quarter 2024 Financial Results.
  4. GlobeNewswire: EMPAVELI (Pegcetacoplan) Drug Insight and Market Forecasts.
  5. Apellis Pharmaceuticals: Apellis Pharmaceuticals Reports Third Quarter 2023 Financial Results.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.